Fig. 12

Evaluation of immune checkpoint profiles and immunotherapy between risk groups. A The expression of immune checkpoints between high-risk group and low-risk group. B Correlation analysis between immune checkpoints and risk scores. C Comparison of the scores of TIDE between the high and low risk group. D The relationship between risk score and RNAss. E The relationship between risk score and sorafenib senstivity (IC50). F Comparison of the sorafenib senstivity (IC50) between the high and low risk group